FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida in the United States, today announced the first patients in Brazil will receive a Stimwave Wireless Pain Relief® device for the treatment of chronic pain. The minimally-invasive procedures will be completed prior to and during the 4thConference of the Brazilian Society of Interventional Pain Physicians (BSIPP) when the leading authorities in the field of pain management gather in Campinas, São Paolo, Brazil from July 6-9, 2017.
Charles Amaral de Oliveira, MD of Singular Centro de Controle da Dor in Campinas, Sao Paolo will perform the procedures as part of the conference’s focus on new trends in neuromodulation. The patients will receive Stimwave’s Wireless Pain Relief® technology as a non-opioid alternative to treating chronic pain. Singular is the first Brazilian pain treatment center to earn the International Excellence in Pain Practice Award from the World Institute of Pain (WIP), as well Singular’s medical staff being the first Brazilian doctors to earn Fellow in Interventional Pain Practice (FIPP) accreditations.
“We expect to improve the quality of life for our patients by allowing them to perform day-to-day activities with more freedom,” said Oliveira. “We already know about 85 percent of people who have spine problems will need an MRI in five years, and Stimwave offers no impediment to this exam, which represents another important achievement.”
The leading authorities in the field of pain management will convene in Campinas, São Paulo from July 6-9 for the 4th Conference of the Brazilian Society of Interventional Pain Physicians. The scientific program includes over 50 activities, including educational lectures by 13 international guest speakers and nine live surgical demonstration procedures to be held July 6. The event’s multidisciplinary focus and comprehensive program features talks on craniofacial pain, neuropathic pain, cancer pain, neck and back pain, the role of ultrasound as an important tool in diagnosing the causes of pain, and on new trends in neuromodulation, as well as the social impact of pain and the standardization of pain professional-health insurance provider relations.
Stimwave has pioneered the Stimwave Freedom Spinal Cord Stimulation (SCS) System and the StimQ Peripheral Nerve Stimulator (PNS) System. Stimwave’s devices are 95 percent smaller than any other neuromodulation device on the market and are the only system to have full body 3T MRI Conditionality. Representing a life-changing technological breakthrough for the more than 400 million people who endure daily chronic pain worldwide, the Stimwave Freedom Spinal Cord Stimulation (SCS) System is the most versatile system available in the industry. The Freedom-8A SCS System can provide patients with up to 64 electrode contacts and offer traditional programming options, as well as other programming options, including frequencies up to 10,000 Hz or waveform customization. The Freedom-8A SCS System with eight electrodes continues to utilize the Apple iPad programmer, leveraging Bluetooth protocols for ease of use in programming the variety of options. The devices deliver small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief.
For more information, visit www.stimwave.com.
Stimwave LLC is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management. www.stimwave.com
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
Glodow Nead Communications
Evan Nicholson, Sonia Sparks, Kati Stadum, and Sarah Rogers, 415-394-6500